Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

ADC Therapeutics SA Common Shares (NY:ADCT)

1.845 -0.125 (-6.35%)
Streaming Delayed Price Updated: 11:47 AM EDT, May 22, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about ADC Therapeutics SA Common Shares

< Previous 1 2 3 4 Next >
Which stocks are moving on Wednesday?
Let's have a look at what is happening on the US markets one hour before the close of the markets on Wednesday. Below you can find the top gainers and losers in today's session. 
Via Chartmill
Top movers analysis in the middle of the day on 2025-05-14: top gainers and losers in today's session.
Curious about what's happening in today's session? Check out the latest stock movements and price changes. 
Via Chartmill
A Preview Of ADC Therapeutics's Earnings
Via Benzinga
ADC Therapeutics Faces Competitive Oncology Market But Analyst Sees 100% Upside - Here's Why
Stephens initiates coverage on ADC Therapeutics (ADCT), highlighting Zynlonta's potential in second-line DLBCL and a promising oncology pipeline. Overweight rating, $6 price target. 
Via Benzinga
ADC Therapeutics's Earnings: A Preview
Via Benzinga
A Preview Of ADC Therapeutics's Earnings
Via Benzinga
ADC Therapeutics - Time For A Turn-Around?
ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates for patients suffering from hematological malignancies and solid tumors. 
Via Talk Markets
Earnings Scheduled For May 14, 2025
Via Benzinga
Preview: ADC Therapeutics's Earnings
Via Benzinga
Earnings Scheduled For March 27, 2025
Via Benzinga
ADCT Stock Earnings: ADC Therapeutics Beats EPS, Misses Revenue for Q2 2024
ADCT stock results show that ADC Therapeutics beat analyst estimates for earnings per share but missed on revenue for the second quarter of 2024. 
Via InvestorPlace
Analyst Expectations for ADC Therapeutics's Future
Via Benzinga
The Latest Analyst Ratings for ADC Therapeutics
Via Benzinga
A Preview Of ADC Therapeutics's Earnings
Via Benzinga
4 Analysts Have This to Say About ADC Therapeutics
Via Benzinga
7 Growth Stocks to Buy for Under $5 for Massive Gains
Although growth stocks under $5 are inherently risky and unpredictable, their very nature also facilitates robust upside potential. 
Via InvestorPlace
Intapp, ServiceNow And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Via Benzinga
Stocks to Buy: 3 Biotech Bargains Delivering Breakthroughs on a Budget
Since wealth without health is utterly meaningless, investors may have some confidence with these biotech stocks to buy. 
Via InvestorPlace
ADCT Stock Earnings: ADC Therapeutics Beats EPS, Misses Revenue for Q1 2024
ADCT stock results show that ADC Therapeutics beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024. 
Via InvestorPlace
BioNTech Reports Downbeat Earnings, Joins Medical Properties Trust And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Via Benzinga
Medifast Reports Mixed Results, Joins Coursera, Chegg And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Via Benzinga
Dollar Tree Reports Weak Earnings, Joins Tesla, Arcos Dorados And Other Big Stocks Moving Lower On Wednesday
U.S. stocks were mixed, with the Dow Jones index surging more than 100 points on Wednesday. 
Via Benzinga
Topics Stocks
Exposures US Equities
Alaska Air To Rally Around 36%? Here Are 10 Top Analyst Forecasts For Tuesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga
The 3 Biotech Stocks That Could Make Your February Unforgettable
After a blistering hot year of biotech M&A, we’ll see more of the same in 2024. That could be great news for these hot biotech stocks. 
Via InvestorPlace
Earnings Scheduled For March 13, 2024
Companies Reporting Before The Bell • Sangamo Therapeutics (NASDAQ:SGMO) is likely to report quarterly loss at $0.26 per share on revenue of $8.10 million. 
Via Benzinga
The 3 Most Undervalued Biotech Stocks to Buy in February 2024
With patience, some of the most undervalued biotech stocks can create massive wealth, such as these three to consider. 
Via InvestorPlace
Why BEST Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket
Gainers Carbon Revolution Public Limited (NASDAQ: CREV) shares surged 358% to $134.37 in pre-market trading after gaining 100% on Friday. The company’s stock began trading on Friday following merger... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 10, 2023
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
  On Tuesday, 56 companies set new 52-week lows. 
Via Benzinga
Stocks That Hit 52-Week Lows On Monday
  On Monday morning, 70 companies achieved new lows for the year. 
Via Benzinga
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.